Haoxi Health Technology Limited
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $32.8M | $48.5M | $28.2M | $16.2M |
| Cost of Revenue | $31.9M | $45.8M | $26.2M | $15.5M |
| Gross Profit | $927.8K | $2.8M | $2.1M | $648.7K |
| Gross Margin | 2.8% | 5.7% | 7.3% | 4.0% |
| Operating Expenses | ||||
| Research & Development | $79.5K | $80.0K | $58.2K | $102.5K |
| SG&A Expense | $2.8M | $911.5K | $776.0K | $239.9K |
| Operating Income | $-2.0M | $1.7M | $1.2M | $268.8K |
| Operating Margin | -6.1% | 3.5% | 4.2% | 1.7% |
| Interest Expense | $46.0K | $41.2K | $19.8K | — |
| Pretax Income | $4.1M | $1.7M | $1.2M | $259.6K |
| Income Tax Expense | $270.7K | $443.6K | $220.7K | $15.0K |
| Net Income | $3.9M | $1.3M | $969.8K | $244.6K |
| Net Margin | 11.8% | 2.7% | 3.4% | 1.5% |
| EPS (Basic) | $1.66 | $1.06 | $0.87 | $0.01 |
| EPS (Diluted) | $1.32 | $1.06 | $0.87 | $0.01 |
| Shares Outstanding (Basic) | 2.3M | 1.2M | 1.1M | 25.0M |
| Shares Outstanding (Diluted) | 2.4M | 1.2M | 1.1M | 25.0M |
| Dividends Per Share | — | — | — | — |